In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? - PubMed (original) (raw)

Review

In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Marie-Francoise Chesselet. Exp Neurol. 2008 Jan.

Abstract

Mutations in alpha-synuclein were the first genetic defect linked to Parkinson's disease (PD). The relevance of alpha-synuclein to sporadic PD is strongly supported by the presence of alpha-synuclein aggregates in neurons of patients. This has prompted the development of numerous animal models based on alpha-synuclein overexpression, primarily through genetic methods in mice and viral transduction in rats. In mice, different promoters and transgenes lead to a wide variety of phenotypes accompanied by non-existent, late onset, or non-specific neurodegeneration. Rapid neurodegeneration, in contrast, is observed after viral transduction but is limited to the targeted region and does not mimic the broad pathology observed in the disease. Overall, each model reproduces a subset of features of PD and can be used to identify therapeutic targets and test disease-modifying therapies. The predictive value of all models of the disease, however, remains speculative in the absence of effective neuroprotective treatments for PD in humans.

PubMed Disclaimer

Similar articles

• rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
  Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C, Baekelandt V. Oliveras-Salvá M, et al. Mol Neurodegener. 2013 Nov 25;8:44. doi: 10.1186/1750-1326-8-44. Mol Neurodegener. 2013. PMID: 24267638 Free PMC article.
• How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
  Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS. Volpicelli-Daley LA, et al. J Neurochem. 2016 Oct;139 Suppl 1(Suppl 1):131-155. doi: 10.1111/jnc.13627. Epub 2016 May 4. J Neurochem. 2016. PMID: 27018978 Free PMC article. Review.
• Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
  Ulusoy A, Decressac M, Kirik D, Björklund A. Ulusoy A, et al. Prog Brain Res. 2010;184:89-111. doi: 10.1016/S0079-6123(10)84005-1. Prog Brain Res. 2010. PMID: 20887871 Review.
• A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.
  Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH. Henrich MT, et al. Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1. Acta Neuropathol Commun. 2018. PMID: 29747690 Free PMC article.
• Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?
  Olanow CW, Brundin P. Olanow CW, et al. Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Mov Disord. 2013. PMID: 23390095 Review.

Cited by

• 25-Hydroxyvitamin D depletion does not exacerbate MPTP-induced dopamine neuron damage in mice.
  Dean ED, Mexas LM, Cápiro NL, McKeon JE, DeLong MR, Pennell KD, Doorn JA, Tangpricha V, Miller GW, Evatt ML. Dean ED, et al. PLoS One. 2012;7(7):e39227. doi: 10.1371/journal.pone.0039227. Epub 2012 Jul 2. PLoS One. 2012. PMID: 22768297 Free PMC article.
• The structure of dopamine induced alpha-synuclein oligomers.
  Rekas A, Knott RB, Sokolova A, Barnham KJ, Perez KA, Masters CL, Drew SC, Cappai R, Curtain CC, Pham CL. Rekas A, et al. Eur Biophys J. 2010 Sep;39(10):1407-19. doi: 10.1007/s00249-010-0595-x. Epub 2010 Mar 23. Eur Biophys J. 2010. PMID: 20309679
• The A30P α-synuclein mutation decreases subventricular zone proliferation.
  Zhang XM, Anwar S, Kim Y, Brown J, Comte I, Cai H, Cai NN, Wade-Martins R, Szele FG. Zhang XM, et al. Hum Mol Genet. 2019 Jul 15;28(14):2283-2294. doi: 10.1093/hmg/ddz057. Hum Mol Genet. 2019. PMID: 31267130 Free PMC article.
• Advancements in CRISPR-Based Therapies for Genetic Modulation in Neurodegenerative Disorders.
  Bhushan B, Singh K, Kumar S, Bhardwaj A. Bhushan B, et al. Curr Gene Ther. 2024;25(1):34-45. doi: 10.2174/0115665232292246240426125504. Curr Gene Ther. 2024. PMID: 38738727 Review.
• Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.
  Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Dong-Chen X, et al. Signal Transduct Target Ther. 2023 Feb 21;8(1):73. doi: 10.1038/s41392-023-01353-3. Signal Transduct Target Ther. 2023. PMID: 36810524 Free PMC article. Review.

References

1. 1. Bensadoun JC, Deglon N, Tseng JL, Ridet JL, Zurn AD, Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol. 2000;164:15–24. - PubMed
2. 1. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx. 2005;2:484–494. - PMC - PubMed
3. 1. Chen L, Feany MB. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci. 2005;8:657–663. - PubMed
4. 1. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39:889–909. - PubMed
5. 1. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain. 2007;130:799–815. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information